Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection

Andrea Kroeker; Bryan D Griffin; Xiangguo Qiu; Gary Kobinger

doi:10.1007/978-1-4939-7116-9_22

Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection

Methods Mol Biol. 2017:1628:273-282. doi: 10.1007/978-1-4939-7116-9_22.

Authors

Andrea Kroeker^{1

2}, Bryan D Griffin^{1

2}, Xiangguo Qiu^{1

2}, Gary Kobinger^{3

4

5}

Affiliations

¹ National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
² Department of Microbiology, University of Manitoba, Winnipeg, MB, Canada.
³ Department of Microbiology, University of Manitoba, Winnipeg, MB, Canada. gary.kobinger@crchudequebec.ulaval.ca.
⁴ Department of Infectious Diseases, Université Laval, Québec, QC, Canada. gary.kobinger@crchudequebec.ulaval.ca.
⁵ Department of Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. gary.kobinger@crchudequebec.ulaval.ca.

PMID: 28573628
DOI: 10.1007/978-1-4939-7116-9_22

Abstract

Mouse models of Ebola virus (EBOV) have demonstrated their utility as important tools for screening the efficacy of candidate therapeutics and vaccines. In this chapter we explain the various mouse models that utilize either wild-type or mouse-adapted EBOV variants.

Keywords: Animal model; Antiviral; Drug therapy; Ebola virus; Monoclonal antibodies; Mouse; Recombinant vesicular stomatitis virus (rVSV); Vaccine.

MeSH terms

Animals
Antibodies, Viral / immunology
Antibodies, Viral / pharmacology
Antiviral Agents / pharmacology
Disease Models, Animal
Ebola Vaccines / pharmacology*
Ebolavirus / drug effects*
Ebolavirus / immunology
Ebolavirus / pathogenicity
Hemorrhagic Fever, Ebola / drug therapy*
Hemorrhagic Fever, Ebola / immunology
Hemorrhagic Fever, Ebola / virology
Humans
Mice

Substances

Antibodies, Viral
Antiviral Agents
Ebola Vaccines